Cassava Sciences, Inc. announced the completion of patient enrollment in a pivotal Phase 3 clinical trial. Eight hundred four (804) Alzheimer?s patients are enrolled in this 12-month trial. A second Phase 3 clinical trial with a target enrollment of approximately 1,100 patients is expected to complete patient enrollment in fourth quarter of 2023.

Both on-going Phase 3 clinical trials are evaluating the safety and efficacy of oral simufilam in patients with Alzheimer's disease dementia. Simufilam is Cassava Sciences? proprietary oral drug candidate.

This investigational drug binds to altered filamin A protein in the brain and restores its normal shape and function. By targeting altered filamin A, simufilam may help patients with Alzheimer?s achieve better health outcomes. The news comes on the heels of a recently announced positive interim safety review of simufilam in Cassava Sciences?

on-going Phase 3 clinical trials in Alzheimer?s disease. A recent meeting of a Data and Safety Monitoring Board (DSMB) recommended that both Phase 3 studies of simufilam continue as planned, without modification.